Elderly and frail nursing home residents, who could have significantly benefited from antiviral treatments for COVID-19, received inadequate amounts of the medication following their coronavirus infections, even when Pfizer Inc’s Paxlovid pill was readily available.
The prescribing data study was conducted by researchers at the University of Rochester and Harvard University, who analyzed data reported to Medicare by nursing homes under specific pandemic requirements.
